Total Payments
$10,377
2024 Payments
$1,490
Companies
40
Transactions
506
Medicare Patients
14,257
Medicare Billing
$2.4M
Payment Breakdown by Category
Food & Beverage$9,587 (92.4%)
Travel$417.09 (4.0%)
Education$373.21 (3.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,587 | 485 | 92.4% |
| Travel and Lodging | $417.09 | 1 | 4.0% |
| Education | $373.21 | 20 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,573 | 79 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,458 | 80 | $0 (2024) |
| Boston Scientific Corporation | $955.62 | 19 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $913.56 | 67 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $578.03 | 29 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $503.87 | 25 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $498.30 | 22 | $0 (2024) |
| Merck Sharp & Dohme LLC | $426.82 | 24 | $0 (2024) |
| CVRx, Inc. | $393.62 | 8 | $0 (2024) |
| PFIZER INC. | $388.38 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,490 | 58 | AstraZeneca Pharmaceuticals LP ($170.42) |
| 2023 | $1,679 | 74 | ABBVIE INC. ($283.35) |
| 2022 | $1,245 | 63 | CVRx, Inc. ($189.77) |
| 2021 | $1,037 | 57 | Novartis Pharmaceuticals Corporation ($225.49) |
| 2020 | $561.37 | 30 | Novartis Pharmaceuticals Corporation ($147.92) |
| 2019 | $1,186 | 69 | Amgen Inc. ($310.11) |
| 2018 | $2,153 | 84 | Boston Scientific Corporation ($708.68) |
| 2017 | $1,025 | 71 | Novartis Pharmaceuticals Corporation ($163.11) |
All Payment Transactions
506 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $30.32 | General |
| Category: Cardiovascular | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.45 | General |
| Category: Cardiovascular | ||||||
| 12/05/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/04/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $24.21 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/21/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: Cardiology | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/31/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: Diabetes | ||||||
| 10/25/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/24/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $126.75 | General |
| Category: Endocrinology | ||||||
| 10/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: NEUROSCIENCE | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: DIABETES | ||||||
| 10/03/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $24.74 | General |
| Category: Cardiology | ||||||
| 09/27/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.16 | General |
| 09/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.71 | General |
| Category: DIABETES | ||||||
| 09/18/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/05/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: Cardiology | ||||||
| 08/16/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $18.94 | General |
| 08/15/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Obesity | ||||||
| 08/14/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/08/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Cardiology | ||||||
| 08/02/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/31/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $28.73 | General |
| Category: Cardiology | ||||||
| 07/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $26.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/16/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $37.60 | General |
| Category: WATCHMAN FLX_IC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 2,880 | 6,227 | $1.7M | $493,641 |
| 2022 | 31 | 3,321 | 7,462 | $1.9M | $604,356 |
| 2021 | 31 | 4,152 | 8,271 | $2.2M | $691,776 |
| 2020 | 35 | 3,904 | 8,227 | $2.1M | $617,006 |
Total Patients
14,257
Total Services
30,187
Medicare Billing
$2.4M
Procedure Codes
127
All Medicare Procedures & Services
127 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 610 | 2,570 | $449,750 | $254,099 | 56.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 138 | 138 | $227,700 | $51,577 | 22.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 221 | 227 | $227,000 | $36,165 | 15.9% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 128 | 512 | $102,400 | $22,570 | 22.0% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 141 | 282 | $141,000 | $21,383 | 15.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 84 | 84 | $33,600 | $14,924 | 44.4% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 18 | 19 | $22,800 | $13,966 | 61.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 588 | 1,083 | $135,375 | $12,678 | 9.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 152 | 155 | $69,750 | $8,209 | 11.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 34 | 77 | $13,475 | $7,601 | 56.4% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 53 | 112 | $22,400 | $7,030 | 31.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 41 | 41 | $24,600 | $6,371 | 25.9% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 91 | 91 | $36,400 | $5,060 | 13.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 32 | $12,800 | $4,604 | 36.0% |
| 93241 | Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 20 | 20 | $8,000 | $4,558 | 57.0% |
| 93290 | Evaluation of implantable heart and blood vessel monitoring system | Office | 2023 | 33 | 89 | $8,900 | $3,277 | 36.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 56 | 59 | $59,000 | $3,277 | 5.6% |
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2023 | 15 | 39 | $6,825 | $3,224 | 47.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 20 | $4,500 | $2,839 | 63.1% |
| 93283 | Programming of dual lead implantable defibrillator system | Office | 2023 | 11 | 23 | $3,450 | $1,701 | 49.3% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 40 | 69 | $10,350 | $1,458 | 14.1% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 48 | 82 | $12,300 | $1,413 | 11.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 40 | 41 | $2,050 | $1,337 | 65.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 182 | 217 | $7,812 | $1,263 | 16.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 15 | 72 | $3,240 | $1,220 | 37.7% |
About Dr. Anil Rastogi, MD
Dr. Anil Rastogi, MD is a Cardiovascular Disease healthcare provider based in Hemet, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659455202.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anil Rastogi, MD has received a total of $10,377 in payments from pharmaceutical and medical device companies, with $1,490 received in 2024. These payments were reported across 506 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($9,587).
As a Medicare-enrolled provider, Rastogi has provided services to 14,257 Medicare beneficiaries, totaling 30,187 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 127 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Hemet, CA
- Active Since 10/24/2006
- Last Updated 04/03/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1659455202
Products in Payments
- Repatha (Biological) $1,293
- ENTRESTO (Drug) $1,157
- XARELTO (Drug) $903.34
- WATCHMAN (Device) $805.64
- VERQUVO (Drug) $426.82
- ELIQUIS (Drug) $401.37
- Barostim Neo System (Device) $393.62
- JARDIANCE (Drug) $363.36
- NEXLETOL (Drug) $325.51
- PRALUENT (Drug) $313.36
- LEQVIO (Drug) $300.61
- Corlanor (Drug) $246.30
- FARXIGA (Drug) $238.99
- MULTAQ (Drug) $190.51
- QULIPTA (Drug) $182.50
- PRADAXA (Drug) $178.72
- BRILINTA (Drug) $146.78
- CHANTIX (Drug) $132.75
- Arcalyst (Drug) $131.45
- Korlym (Drug) $126.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Hemet
Dr. Ratan Tiwari, M.d, M.D
Cardiovascular Disease — Payments: $8,855
Cardiovascular Disease $8,855
Dr. Betty Grant-Anderson, M.d, M.D
Cardiovascular Disease — Payments: $6,547
Cardiovascular Disease $6,547
Dr. Jose Dimen, M.d, M.D
Cardiovascular Disease — Payments: $2,559
Cardiovascular Disease $2,559
Shivang Shah, Md, MD
Cardiovascular Disease — Payments: $1,909
Cardiovascular Disease $1,909
Dipeshkumar Gandhi, Md, MD
Cardiovascular Disease — Payments: $487.92
Cardiovascular Disease $487.92
Dr. Mariana Ciobanu, Md, MD
Cardiovascular Disease — Payments: $238.05
Cardiovascular Disease $238.05